Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

Innovus Pharmaceuticals, Inc. (INNV)

Add INNV Price Alert      Hide Sticky   Hide Intro
Moderator: BooDog, kkpennies, John Kent, NewTrader2017
Search This Board: 
Last Post: 12/10/2017 6:51:10 PM - Followers: 139 - Board type: Free - Posts Today: 4
* shareholders, please consider purchasing product(s)


Awaiting Official Announcement of FDA Approval for FlutiCare

FlutiCare Approval could bring a BILLION DOLLARS in sales annually

REDONDO BEACH, CA--(Marketwired - Jul 12, 2016) -, a leading financial news and information portal offering free real time public company filing alerts, discusses the potential impact of the anticipated FDA ruling on Innovus Pharmaceuticals' (OTCQB: INNV) ANDA filing for FlutiCare™, the company's over-the-counter treatment for allergic rhinitis.

FlutiCare™ is designed to treat non-allergic rhinitis -- better known as "hay fever" or "stuffy nose" -- which affects roughly 50 million Americans each year. While 70% of these individuals use over-the-counter products, more than half are not satisfied with the treatment option, according to an Asthma and Allergy Foundation of America survey, which suggests there's an opportunity for a prescription-strength OTC treatment option to capture market share from category leaders.

As the #1 prescription nasal steroid with over 177 million units sold since 2007, Innovus believes that the over-the-counter version of FlutiCare™ could be worth up to $1 billion per year by addressing a much wider over-the-counter market. The FDA decision is expected in the next several weeks.


The CEO has already signed an agreement for the manufacturing of FlutiCare

Innovus Pharma Achieves Major Milestone With Securing a Manufacturing Agreement for FlutiCare in Anticipation of the FDA Decision

SAN DIEGO, CA--(Marketwired - May 31, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced that it signed a manufacturing agreement for the supply of its FlutiCare™ 60 and 120 spray/bottles.  Innovus signed the agreement in anticipation of the FDA's decision, expected between July-September of this year, on the ANDA application for the drug.


Prior to joining Innovus Pharma,

Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. 
where he helped move the company's stock price from
19 Cents to $6.00 !!!
(Uplisted from OTC to NASDAQ)


Company Profile:

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

Business Summary:

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The company?s pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was incorporated in 2011 and is based in San Diego, California.

Bassam Damaj, Ph.D.
President and Chief Executive Officer:

Dr. Bassam Damaj was appointed to serve as our President and Chief Executive Officer in January 2013. Prior to joining Innovus Pharma, Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company, from December 2009 until November 2012. At Apricus Bio, Dr. Damaj was responsible for the approval of its lead drug Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. Before Apricus Bio, Dr. Damaj was a co-founder of Bio-Quant, Inc. and served as the Chief Executive Officer and Chief Scientific Officer and a Director of Bio-Quant's board of directors from its inception in June 2000 until its acquisition by Apricus Biosciences in December 2009. In addition, Dr. Damaj was the founder, Chairman, President and Chief Executive Officer of R&D Healthcare, and the co-founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was a Member of the Scientific Advisory Board of MicroIslet, Inc. He is the author of the Immunological Reagents and Solutions reference book, the inventor of many patents and author of numerous peer reviewed scientific publications. Dr. Damaj won a US Congressional award for the Anthrax Multiplex Diagnostic Test in 2003. Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University.

Who are the major players at Innovus Pharma?


Share Structure:

Shares Outstanding:     150.5 Million (as of 4/28/17)   Dr. Damaj owns $23.7M shares.  Novalere owns 25.6M.  One person and One Entity own ~ 32.8% of the outstanding shares. 

Profitability expected exiting Q4 2017 !
- 2017 Projected Revenue of $15M (NOT counting FlutiCare), which would be approximately 3x GREATER than 2016. 


Company Videos:

Innovus Pharma CEO Provides Shareholder Update and Conference Call

Corporate Presentation November 2016 (8-K  11/1/2016)

Upcoming PDUFA and ANDA Approval Dates Could Catalyze Innovus Pharma (INNV) and Lipocine (LPCN)

Innovus Pharma (INNV): Targeting $3+ Billion Markets With 13 Commercial Products

Major 2016 Accomplishments:



Where can INNV products be seen?


Existing Product Lines @ Innovus Pharma:

Newest Product:


PROSTAGORX™ is a clinical strength, multi response prostate supplement, scientifically formulated to effectively maintain good prostate health and help in prevent prostate issues in the future. ProstaGorx™ was developed by top medical doctors and produced in a top-quality, cGMP certified and FDA registered laboratory environment under the most rigorously professional conditions. 

The positive benefits provided by the individual and combination ingredients in ProstaGorx™ have been published in leading medical journals.


Are you looking to boost your brain health?r

** Help to get the word out and be a PRODUCT AMBASSADOR for YOUR company

Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
INNV News: Quarterly Report (10-q) 11/14/2017 04:41:42 PM
INNV News: Current Report Filing (8-k) 11/14/2017 04:24:20 PM
INNV News: Current Report Filing (8-k) 11/14/2017 06:13:49 AM
INNV News: Statement of Changes in Beneficial Ownership (4) 10/02/2017 04:57:33 PM
INNV News: Statement of Changes in Beneficial Ownership (4) 10/02/2017 04:56:09 PM
#12575  Sticky Note Looks like Zack's like us again kkpennies 11/24/17 03:04:12 PM
#12430  Sticky Note !!! $INNV Investor Starter Guide !!!! John Kent 11/20/17 10:31:19 AM
#11803  Sticky Note $19B market. I think I'd be loading up BooDog 10/03/17 06:04:18 AM
#12843   It WILL happen, we just don't know when. Batermere 12/10/17 06:51:10 PM
#12842   I hope so Clev3land. gi197845 12/10/17 06:43:42 PM
#12841   Ladies and Gents... Just a basic example of jbdiver 12/10/17 05:47:27 PM
#12840   Get ready I feel the original ANDA IS Clev3land 12/10/17 10:41:30 AM
#12839   I doubt he reads any forums. I don't ShawnP123 12/08/17 08:13:58 AM
#12838   Shawn, I know Dr.Damaj reads this forum, so gi197845 12/07/17 08:35:21 PM
#12837   Yep - he'll need cash soon enough and Honeycomb777 12/07/17 04:23:22 PM
#12836   Maybe he needs to hire 2 more people ShawnP123 12/07/17 04:12:42 PM
#12835   Thanks for the update. Most of us can Batermere 12/07/17 03:34:41 PM
#12834   back to the comfortable, stagnant .08's. The next twistedfreak 12/07/17 03:12:43 PM
#12833   (Healthywelth, it's quite amazing how profitability was projected healthywelth 12/07/17 12:32:12 PM
#12832   Healthywelth, it's quite amazing how profitability was projected gi197845 12/07/17 11:38:51 AM
#12830   9.6M in revs for 2017 IMO - a Honeycomb777 12/06/17 11:06:50 PM
#12829   HC- Q4 will be down about 10-15% on ShawnP123 12/06/17 09:59:44 PM
#12828   I have coins but home alone ! Honeycomb777 12/06/17 08:43:50 PM
#12827   Its Ok , Honeycomd - we have time healthywelth 12/06/17 08:25:16 PM
#12826   Longs - you do realize that every single Honeycomb777 12/06/17 08:16:14 PM
#12825   INNV - have grown revenues from $800k in healthywelth 12/06/17 07:49:08 PM
#12824   Think about . No need to will healthywelth 12/06/17 07:14:02 PM
#12823   I believe it waiting patiently here John Kent 12/06/17 05:04:39 PM
#12822   I saw a Yahoo article, indicating Viagra is gi197845 12/06/17 01:57:13 PM
#12821   Good post, Jeffrey Dahmer. gi197845 12/06/17 01:04:52 PM
#12820   2018 runner john Dahmer 12/06/17 11:46:03 AM
#12819   Lol, at this point, I don't have the gi197845 12/05/17 01:46:42 PM
#12818   Hmmm. A micro investor. Sounds rather inconsequential in twistedfreak 12/05/17 01:24:22 PM
#12817   lol John Kent 12/05/17 12:59:10 PM
#12816   Is it PIS projections or PISS projections? It's gi197845 12/05/17 12:44:00 PM
#12815   Not out of business. But I do believe ShawnP123 12/05/17 12:37:36 PM
#12814   Phew, I'm sure glad you cleared that up twistedfreak 12/05/17 12:28:31 PM
#12813   TwistedFreak, boiler room was a generic term for gi197845 12/05/17 12:14:38 PM
#12812   Shawn, do you think INNV will go out gi197845 12/05/17 12:12:11 PM
#12811   Boiler room? I live in the Southeast. We twistedfreak 12/05/17 11:39:31 AM
#12810   gi- high risk if you think about averaging ShawnP123 12/05/17 11:19:58 AM
#12809   TwistedFreak, with all the money you've made for gi197845 12/05/17 10:57:13 AM
#12808   Well, if it goes down to .06, that gi197845 12/05/17 10:37:54 AM
#12805   They need to cross sell these products to Honeycomb777 12/04/17 03:06:53 PM
#12804   Most of the products have been out for ShawnP123 12/04/17 03:01:56 PM
#12803   Awesome news we are getting close here few John Kent 12/04/17 02:28:03 PM
#12801   The product names are fine and they are gi197845 12/04/17 02:13:47 PM
#12798   Why's that, G? I think you're mistaken. There's twistedfreak 12/04/17 01:34:53 PM
#12796   More NEWS OUT TODAY...... learningthetruth 12/04/17 09:09:20 AM
#12795   INNOVUS PHARMA (INNV) Shorts Down By 47.9% kkpennies 12/03/17 06:44:41 PM
#12792   Thank You for serving GI Joe Honeycomb777 12/02/17 02:34:07 PM
#12791   Ok, I understand, thanks. gi197845 12/02/17 02:29:24 PM
#12790   292.5 will soon be the max o/s and Honeycomb777 12/02/17 02:23:10 PM
#12789   Huh, what's 292.5? I know what an rs is. gi197845 12/02/17 02:12:49 PM
#12788   I see 292.5 coming and then an rs Honeycomb777 12/02/17 02:04:49 PM
#12787   Well Honeycomb, this is a reason for the gi197845 12/02/17 12:52:23 PM
#12786   And 26M would be exercised IMMEDIATELY once it Honeycomb777 12/02/17 11:20:02 AM
#12784   50M shares on 159M float. That's over 30% twistedfreak 12/02/17 08:08:15 AM